From Two Relapses a Year to None in 16 Months
GenoMed Trial Results: Multiple Sclerosis –
From Two Relapses a Year to None in 16 Months
Another drug appears to be effective in redusing MS brain lesions
“Immunosuppressive Drug Appears Effective in Reducing New Brain Lesions in Multiple Sclerosis Patients”
Viking Gene in MS
A Norse Contribution to the History of Neurological Diseases.
Department of Neurology, Ulleval University Hospital, Oslo, Norway.
Multiple sclerosis (MS) is prevalent in areas with many inhabitants of Scandinavian descent, and a ‘Viking gene’ hypothesis has been suggested for the dissemination of the disease. It is therefore, relevant to search Norse (from West Scandinavian (Norwegian, Icelandic, and Faeroese) sagas (stories or legends)… read more »
study on oligoclonal bands in RRMS
Absence of cerebrospinal fluid oligoclonal bands is associated with delayed disability progression in relapsing-remitting MS patients treated with interferon-beta.
Department of Neurological Sciences and Behaviour, University of Siena, Italy.
To assess the role of cerebrospinal fluid oligoclonal bands in determining the clinical outcome in patients with relapsing-remitting multiple sclerosis (RRMS) treated with interferon-beta, we carried out a retrospective, multi-centre, observational study Recruiting 209 RRMS patients… read more »
Why is fatigue often so hard for friends and family to understand?
Beyond Just Tired: Figuring Out MS-Related Fatigue
TYSABRI Multiple Sclerosis Clinical Trial Hold Lifted
TYSABRI(R) Multiple Sclerosis Clinical Trial Hold Lifted by FDA; Biogen Idec and Elan to Resume Clinical Trial Dosing in MS
